ERK inhibition sensitizes CZ415-induced anti-osteosarcoma activity in vitro and in vivo

mTOR is a valuable oncotarget for osteosarcoma. The anti-osteosarcoma activity by a novel mTOR kinase inhibitor, CZ415, was evaluated. We demonstrated that CZ415 potently inhibited survival and proliferation of known osteosarcoma cell lines (U2OS, MG-63 and SaOs2), and primary human osteosarcoma cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Gang, Fan, Jin, Zhou, Wei, Ding, Qingfeng, Zhang, Jun, Wu, Xuan, Tang, Pengyu, Zhou, Hao, Wan, Bowen, Yin, Guoyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669867/
https://www.ncbi.nlm.nih.gov/pubmed/29137241
http://dx.doi.org/10.18632/oncotarget.18303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669867/
https://www.ncbi.nlm.nih.gov/pubmed/29137241
http://dx.doi.org/10.18632/oncotarget.18303

Ejemplares similares